@article{7217077c642c4440a96ae4bfbad28a37,
title = "FDA Draft Guidance for Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet: Comments by the Society for the Study of Celiac Disease",
author = "\{SSCD Executive Council\} and \{SSCD Writing Committee\} and Benjamin Lebwohl and Ritu Verma and Ciaran Kelly and Daniel Leffler and Vanessa Weisbrod and \{Roland Lee\}, Anne and Maureen Leonard and Amelie Therrien and Daniel Adelman and Marilyn Geller and Joseph Murray",
note = "Funding Information: Conflicts of interest These authors disclose the following: Dr Adelman has served as a consultant or advisor to Takeda, GSK, Anokion, Equillium, and Protagonist. Ms Geller served as a consultant for ICON. Dr Kelly has served as a consultant or advisor to Cour Pharma, Jansen (J\&J), Kanyos/Anokion, Merck, Milky Way Life Sciences, Takeda, and Teravance; as an Investigator to Merck, Milky Way Life Sciences, and Takeda; and holds stock options in Cour Pharma and Glutenostix. Dr Leonard has served as a consultant to Mozart Therapeutics and Amgen Pharmaceuticals; as an advisory board member for 9 Meters Biopharma; and received research support from Glutenostics LLC. Dr Leffler is an employee of Takeda Pharmaceutical. Dr Murray reports grants from Nexpep/ImmusanT, Immunogenix, Takeda Pharmaceutical, Allakos, Provention Bio, Oberkotter Foundation, and Kanyos/Anokion; and consultancy fees from Johnson \& Johnson, Bristol Myers Squibb, Intrexon Corporation, Dren Bio, Neoleukin, Reistone Pharma, Immunic Therapeutics, Senda Biosciences, Brightseed Bio, Chugai Pharma, Kanyos, Alimentiv, Equillium, Ukko, and Vial Health Technologies; and has received royalties from Torax Medical and Evelo. The remaining authors disclose no conflicts. ",
year = "2023",
month = mar,
doi = "10.1053/j.gastro.2022.07.024",
language = "English (US)",
volume = "164",
pages = "495--496",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders",
number = "3",
}